Comparing Fluorescence Lifetime Imaging Ophthalmoscopy in Atrophic Areas of Retinal Diseases.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
01 06 2021
Historique:
entrez: 10 6 2021
pubmed: 11 6 2021
medline: 29 6 2021
Statut: ppublish

Résumé

Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a non-invasive imaging modality to investigate the human retina. This study compares FLIO lifetimes in different degenerative retinal diseases. Included were eyes with retinal pigment epithelium (RPE) and/or photoreceptor atrophy due to Stargardt disease (n = 66), pattern dystrophy (n = 18), macular telangiectasia type 2 (n = 49), retinitis pigmentosa (n = 28), choroideremia (n = 26), and geographic atrophy (n = 32) in age-related macular degeneration, as well as 37 eyes of 37 age-matched healthy controls. Subjects received Heidelberg Engineering FLIO, autofluorescence intensity, and optical coherence tomography imaging. Amplitude-weighted mean FLIO lifetimes (τm) were calculated and analyzed. Retinal FLIO lifetimes show significant differences depending on the disease. Atrophic areas in geographic atrophy and choroideremia showed longest mean FLIO lifetimes. τm values within areas of RPE and outer nuclear layer atrophy were significantly longer than within areas with preserved outer nuclear layer (P < 0.001) or non-atrophic areas (P < 0.001). FLIO is able to contribute additional information regarding differences in chronic degenerative retinal diseases. Although it cannot replace conventional autofluorescence imaging, FLIO adds to the knowledge in these diseases and may help with the correct differentiation between them. This may lead to a more in-depth understanding of the pathomechanisms related to atrophy and types of progression. Differences between atrophic retinal diseases highlighted by FLIO may indicate separate pathomechanisms leading to atrophy and disease progression.

Identifiants

pubmed: 34110387
pii: 2772690
doi: 10.1167/tvst.10.7.11
pmc: PMC8196421
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

11

Subventions

Organisme : NCRR NIH HHS
ID : UL1 RR025764
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY011600
Pays : United States
Organisme : NEI NIH HHS
ID : R29 EY011600
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000105
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY014800
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001067
Pays : United States

Références

Mol Vis. 1999 Nov 03;5:25
pubmed: 10562649
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4213-9
pubmed: 20220048
Ophthalmic Epidemiol. 2012 Aug;19(4):185-9
pubmed: 22364548
Hum Mol Genet. 2004 Mar 1;13(5):525-34
pubmed: 14709597
Orphanet J Rare Dis. 2006 Oct 11;1:40
pubmed: 17032466
J Biomed Opt. 2018 Sep;23(9):1-20
pubmed: 30182580
Surv Ophthalmol. 2009 May-Jun;54(3):401-7
pubmed: 19422966
Retina. 2016 Dec;36 Suppl 1:S26-S39
pubmed: 28005661
Transl Vis Sci Technol. 2020 Sep 30;9(10):33
pubmed: 33062396
Ophthalmologica. 2020;243(3):195-206
pubmed: 31743906
PLoS One. 2016 Apr 12;11(4):e0151943
pubmed: 27070432
Cell. 1992 Sep 18;70(6):1049-57
pubmed: 1525821
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3992-4001
pubmed: 31560765
Transl Vis Sci Technol. 2020 Aug 03;9(9):2
pubmed: 32879759
PLoS One. 2015 Jul 20;10(7):e0131640
pubmed: 26192624
Arch Ophthalmol. 1982 May;100(5):769-80
pubmed: 7082207
J Fr Ophtalmol. 2018 Jan;41(1):21-29
pubmed: 29195727
Ophthalmic Genet. 2006 Dec;27(4):117-22
pubmed: 17148038
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):832-41
pubmed: 26934141
Ophthalmology. 2015 Jul;122(7):1356-65
pubmed: 25972258
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Curr Eye Res. 2013 Jul;38(7):793-801
pubmed: 23530995
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4668-79
pubmed: 26207302
J Biomed Opt. 2004 Nov-Dec;9(6):1214-22
pubmed: 15568942
Retina. 2008 Jun;28(6):808-16
pubmed: 18536596
Biometrics. 1949 Jun;5(2):99-114
pubmed: 18151955
Curr Opin Ophthalmol. 2016 May;27(3):217-23
pubmed: 26866953
Ophthalmologe. 2002 Oct;99(10):774-9
pubmed: 12376853
Invest Ophthalmol Vis Sci. 2014 Apr 03;55(4):2106-13
pubmed: 24569585
Prog Retin Eye Res. 2017 Sep;60:120-143
pubmed: 28673870
Retina. 2020 Jan;40(1):99-108
pubmed: 30664123
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1051-6
pubmed: 11274085
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD65-AMD77
pubmed: 30025104
Am J Ophthalmol. 2015 Jul;160(1):85-93.e3
pubmed: 25857680
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2479-87
pubmed: 27149697
Am J Ophthalmol. 2007 Mar;143(3):463-72
pubmed: 17239336
Ophthalmology. 1996 Mar;103(3):357-64
pubmed: 8600410
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5186-5191
pubmed: 27699414
Transl Vis Sci Technol. 2018 Jun 22;7(3):20
pubmed: 29946494
Sci Transl Med. 2018 Apr 4;10(435):
pubmed: 29618560
Prog Retin Eye Res. 1999 May;18(3):371-89
pubmed: 10192518
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6714-6721
pubmed: 27951593
Ophthalmol Retina. 2018 Jun;2(6):587-598
pubmed: 30116796
Arch Ophthalmol. 1978 Jul;96(7):1185-8
pubmed: 307377
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4931-4942
pubmed: 31770433
Transl Vis Sci Technol. 2019 May 8;8(3):15
pubmed: 31114715
Clin Ophthalmol. 2015 Nov 23;9:2195-200
pubmed: 26648685
Am J Ophthalmol. 2010 Jul;150(1):55-62.e2
pubmed: 20609708
Retina. 2018 Apr;38(4):731-738
pubmed: 28338556
Am J Ophthalmol. 2008 Apr;145(4):687-94
pubmed: 18242574
Prog Retin Eye Res. 2013 May;34:49-77
pubmed: 23219692
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1769-1778
pubmed: 29610860
Acta Ophthalmol. 2018 May;96(3):257-266
pubmed: 29105362
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFc1-9
pubmed: 27116660
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO61-BIO67
pubmed: 28475704

Auteurs

Lukas Goerdt (L)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.
Department of Ophthalmology, University of Bonn, Bonn, Germany.

Lydia Sauer (L)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Alexandra S Vitale (AS)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Natalie K Modersitzki (NK)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Monika Fleckenstein (M)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Paul S Bernstein (PS)

John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH